title: Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios.
abstract: OBJECTIVE
  To compare the effects of 2.5 mg letrozole with those of 1 mg anastrazole daily on the hormonal and semen profiles of a subset of infertile men with low T/E(2) ratios.
  
  
  METHODS
  Prospective, nonrandomized study.
  
  
  METHODS
  Reproductive medicine clinic.
  
  
  METHODS
  The study group consisted of 29 infertile men with a low serum T/E(2) ratio (<10).
  
  
  METHODS
  Patients were divided into two groups. Group A included 15 patients treated with 2.5 mg letrozole orally once daily for 6 months, and Group B consisted of 14 patients treated with 1 mg anastrazole orally every day for 6 months.
  
  
  METHODS
  Hormonal evaluation included measurement of serum FSH, LH, PRL, T, and E(2). In all sperm analyses pretreatment and posttreatment total motile sperm counts (ejaculate volume × concentration × motile fraction) were evaluated.
  
  
  RESULTS
  The use of aromatase inhibitors (either letrozole or anastrazole) in cases of infertile men with low T/E(2) ratios improved both hormonal and semen parameters.
  
  
  CONCLUSIONS
  This study suggests that some men with severe oligospermia, low T levels, and normal gonadotropin concentration may have a treatable endocrinopathy.
authors.affiliation: 2nd Department of Obstetrics and Gynecology, Aretaieion Hospital, University of Athens, Athens, Greece. xarisgrigoriadis@yahoo.gr
authors.forename: Odysseas
authors.initials: O
authors.lastname: Gregoriou
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Bakas
authors.forename: Charalampos
authors.initials: C
authors.lastname: Grigoriadis
authors.forename: Maria
authors.initials: M
authors.lastname: Creatsa
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Hassiakos
authors.forename: Georgios
authors.initials: G
authors.lastname: Creatsas
mesh_terms: D000328:Adult; D000077384:Anastrozole; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004958:Estradiol / Q000032:analysis / Q000097:blood*; D006728:Hormones / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007248:Infertility, Male / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000077289:Letrozole; D008297:Male; D009570:Nitriles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009929:Organ Size / Q000187:drug effects; D055101:Semen Analysis; D013737:Testis / Q000187:drug effects / Q000473:pathology; D013739:Testosterone / Q000032:analysis / Q000097:blood*; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D047072:Aromatase Inhibitors; D006728:Hormones; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole; D013739:Testosterone; D004958:Estradiol; D000077289:Letrozole